EGFR and neoplasm: Several reasons have been suggested to account for these failures—genetic heterogeneity spanning inter‐tumor and intra‐tumor scales, signaling redundancy, the blood–brain barrier, etc.8, 9, 10, 11Importantly, the profile of EGFR alteration in GBM differs from other solid cancers with sensitivity to EGFR tyrosine kinase inhibitors.